The Horizon of Antiangiogenic Therapy for Colorectal Cancer

March 1, 2005

Vascular endothelial growth factor (VEGF) plays a crucial role inthe growth and metastatic spread of cancer. Bevacizumab (Avastin) isthe first commercially available VEGF inhibitor, earning US Food andDrug Administration (FDA) approval in February 2004. In combinationwith fluorouracil (5-FU)-based chemotherapy, this agent significantlyprolongs overall and progression-free survival of patients withmetastatic colorectal cancer. This review details the emerging role ofthe drug, its unique side effects, and other practical considerations relatedto bevacizumab therapy. Ongoing trials attempting to define additionalindications for bevacizumab as well as the development ofother promising angiogenesis inhibitors are also reviewed.

Vascular endothelial growth factor (VEGF) plays a crucial role in the growth and metastatic spread of cancer. Bevacizumab (Avastin) is the first commercially available VEGF inhibitor, earning US Food and Drug Administration (FDA) approval in February 2004. In combination with fluorouracil (5-FU)-based chemotherapy, this agent significantly prolongs overall and progression-free survival of patients with metastatic colorectal cancer. This review details the emerging role of the drug, its unique side effects, and other practical considerations related to bevacizumab therapy. Ongoing trials attempting to define additional indications for bevacizumab as well as the development of other promising angiogenesis inhibitors are also reviewed.

After more than 30 years of research, antiangiogenesis therapy has become a clinical reality, representing one of the most exciting therapeutic advances in oncology. Of the numerous growth factor- receptor complexes that promote angiogenesis, the vascular endothelial growth factor (VEGF) pathway is of particular importance. Bevacizumab (Avastin), a monoclonal antibody that targets VEGF, is the first such agent to gain US Food and Drug Administration (FDA) approval after a landmark placebo-controlled phase III trial confirmed the efficacy of antiangiogenic therapy in metastatic colon cancer. The availability of bevacizumab as first-line therapy for metastatic colorectal cancer in combination with irinotecan (Camptosar) and fluorouracil (5-FU) has fostered a global effort to further develop this and other anti-VEGF therapies. Trials are either planned or under way to define the role of bevacizumab in the adjuvant setting, to develop additional bevacizumab- based combinations with other chemotherapy agents or novel targeted agents, and to optimize dosing. This article surveys the ongoing development of anti-VEGF-based therapies for colorectal cancer as well as the evaluation and management of side effects unique to this drug class. Role of VEGF in Regulation of Angiogenesis Angiogenesis is a complex process leading to the formation and maintenance of new blood vessels. It involves processing of the extracellu lar matrix as well as cell proliferation and organization, and is regulated by a large number of activating and inhibitory signals.[1] VEGF is a highly specific and potent endothelial cell mitogen, the expression of which is induced primarily by hypoxia.[2,3] VEGF binding sites are present exclusively on vascular endothelium, including quiescent cells, suggesting a role in growth promotion and in survival of established blood vessels.[ 4] An additional and possibly clinically important VEGF activity consists of increasing vascular permeability. The two main VEGF receptors are designated fms-like tyrosine kinase, VEGFR-1 (Flt-1), and fetal liver kinase-1, kinase domain region, VEGFR-2 (Flk-1/KDR).[5]

VEGF in Colorectal Cancer Inadequate angiogenesis results in tumor necrosis and impairs metastatic potential.[6] Similar to other cancers, colorectal adenocarcinomas exhibit an abnormally high level of VEGF mRNA and protein expression with an increased level of both Flt-1 and Flk-1/KDR receptors in adjacent vessels, consistent with a paracrine mechanism.[ 7] Serum levels of VEGF are increased in colorectal cancer and correlate with stage of disease. VEGF overexpression has been validated as a poor prognostic factor.[8-10] Tumor VEGF overexpression predicts for worse outcome in patients with resected stage II disease and elevated preoperative serum VEGF is a poor prognostic factor in both stage II and stage III disease.[11,12] Observational studies indicate that VEGF has an important role in hematogenous metastatic spread of human colon adenocarcinoma and establish a foundation for therapeutic research targeting VEGF and its receptors. Different approaches toward inhibition of VEGF-dependent angiogenesis include the use of monoclonal antibodies against VEGF or its receptors (VEGFR), small-molecule inhibitors of VEGFR-specific tyrosine kinase activity, ribozymes specifically cleaving VEGF/VEGFR mRNA, soluble VEGF receptors acting as a trap for the circulating factor, and antisense oligonucleotides of VEGF mRNA. The clinical development of some of these agents is summarized in Table 1. Existent inhibitors of the VEGF pathway exhibit very limited toxicity and can be combined safely with conventional chemotherapy. Bevacizumab: First Anti-VEGF Agent in Clinical Practice Bevacizumab is a recombinant humanized monoclonal antibody that is able to neutralize all biologically active isoforms of VEGF-A. In murine xenograft models, the anti-VEGF antibody was shown to inhibit the growth of metastatic tumors while it was devoid of cytotoxic activity on cell lines in vitro.[13,14] In a phase I study, no drug-specific grade 3 or 4 toxicities were observed at bevacizumab doses ranging from 0.1 to 10 mg/kg.[15] More common adverse effects were infusion-related asthenia, headache, and fever. An elevation of systolic and diastolic blood pressure of 10 mm Hg on average was noted at higher dose levels. Two patients experienced serious hemorrhages within metastatic tumors. The 21-day half-life of bevacizumab with linear kinetics permits every-14-day dosing. If the bevacizumab dose and schedule is altered to 7.5 mg/kg every 3 weeks, pharmacokinetics and overall dose exposure are similar to the currently standard dosing of 5 mg/kg once every 2 weeks.[16] Major Clinical Trials

  • Phase II Study-Bevacizumab may be administered safely with either irinotecan-, oxaliplatin-, or 5-FU-based chemotherapies with no additive toxicity.[17] As a treatment for metastatic colon cancer, bevacizumab has been combined with 5-FU, leucovorin, 5-FU/irinotecan, and 5-FU/oxaliplatin (Eloxatin) in a variety of phase II protocols with encouraging response rates, time to tumor progression, and median overall survival durations. To date, bevacizumab at 5 mg/kg every other week has been associated with better clinical outcomes than the 10-mg/kg dose when combined with chemotherapy. A three-arm randomized phase II trial compared the Roswell Park regimen of 5-FU/leucovorin alone (bolus 5-FU at 500 mg/m2 with 500 mg/m2 of leucovorin weekly for 6 weeks every 8 weeks) with either 5 or 10 mg/kg of bevacizumab every other week.[18] The median time to disease progression was 5.2 months in the control arm, 9 months in the 5-mg/kg bevacizumab arm (P = .005), and 7.2 months in the 10-mg/kg arm. The decrease in the hazard of progression in the 10-mg/kg group was not statistically significant. An objective response was seen in 40% of patients who received 5 mg/kg of bevacizumab and 17% in the control group (P = .029 compared with the control arm), whereas the difference in response rates for the higher-dose bevacizumab arm did not reach statistical significance (24%, P = .434). Patients in the 5-mg/kg arm had an impressive although not statistically significant 21.5-month median survival compared with 13.8 months in the control arm, despite the fact that 61% of controls crossed over to single-agent bevacizumab therapy upon disease progression.
  • Toxicities were more common in the experimental arms, including grade 3 and 4 events. These side effects are consistent with what is emerging as a bevacizumab-specific toxicity profile, summarized in Table 2. While bevacizumab did not worsen the usual 5-FU/leucovorin-related adverse events (such as gastrointestinal toxicities or myelosuppression), hypertension, thrombotic, and hemorrhagic events were more frequent. The major hemorrhagic event was mild epistaxis lasting less than 5 minutes. Thromboembolic complications included a grade 5 pulmonary embolism in one patient receiving bevacizumab at the 10-mg/kg dose. Notably, the study was partly confounded by imbalances in randomization (more women and slightly worse performance profiles were assigned to the experimental arms). However, both efficacy and toxicity data favored the lower dose of bevacizumab.
  • Phase III Study-The results of AVF2107, a randomized, placebocontrolled phase III trial of bevacizumab in combination with irinotecan and bolus 5-FU/leucovorin (for details of this and other discussed regimens, refer to Figure 1) resulted in FDA approval of bevacizumab as first- line therapy for metastatic colorectal cancer in February 2004.[19] Nine hundred and twenty-three patients with previously untreated metastatic colorectal cancer were assigned to receive either IFL (irinotecan, 5-FU, leucovorin), IFL with bevacizumab, or 5-FU/leucovorin (according to the Roswell Park schedule) with bevacizumab. The dose of bevacizumab was 5 mg/kg every 2 weeks. Notable exclusion criteria included clinically significant cardiovascular disease (encompassing myocardial infarction, stroke, unstable angina, class II-IV congestive heart failure within 1 year, dysrhythmias requiring therapy, uncontrolled hypertension, grade 2 or higher peripheral vascular disease), full-intensity anticoagulation (except for cardiac doses of aspirin), ascites, or proteinuria exceeding 500 mg/d.
  • Median survival, the primary end point, reached statistical significance with outcomes of 20.3 vs 15.6 months (P < .001), in favor of the IFL/bevacizumab combination. Similarly, the progression-free survival (10.6 vs 6.2 months, P < .001) and response rate (44.8% vs 34.8%, P < .004) favored the experimental arm. The survival benefit of adding bevacizumab to IFL was evident in all study subgroups, including patients with advanced age and poor performance status. According to the trial design, once a planned preliminary safety analysis determined the feasibility of the IFL regimen with bevacizumab, accrual to the 5-FU/leucovorin-plus-bevacizumab arm ended. Nevertheless, among 110 evaluable patients, there was a provocative trend toward better survival in the 5-FU/leucovorin/bevacizumab arm (18.3 months) than in the IFL/placebo arm, and the difference in time to disease progression for these two groups reached statistical significance (8.8 vs 6.7 months, P = .03). In this large trial, further insight into the bevacizumab toxicity profile emerged. Side effects associated with the IFL-plus-bevacizumab arm are summarized in Table 2. A greater number of grade 3/4 adverse effects occurred in the IFL/bevacizumab arm (85% vs 74%), chiefly due to hypertension (11% vs 2.3%). Elevated blood pressure has been managed easily with single-agent antihypertensive therapy. The occurrence of gastrointestinal (GI) perforations in patients receiving bevacizumab (including one fatality) is very concerning and seems to represent a drug-specific toxicity. Ongoing efforts will attempt to identify subsets at risk for this side effect. Clinicians must consider GI perforation when patients deteriorate or develop abdominal symptomatology. Interestingly in this trial, no statistically significant increased incidence of severe hemorrhage, proteinuria, or venous thromboembolism was observed. However, a retrospective analysis of thromboembolic events revealed a higher rate of "any" arterial thrombotic event (3.3% vs 1.0%), myocardial infarction (1.5% vs 0.8%), and cerebrovascular accident (0.5% vs 0.0%) in the IFL-plus-bevacizumab arm compared with the IFL-plusplacebo arm.[20] Similarly, study AVF2192g (which included elderly or less fit patients with untreated metastatic colorectal cancer) corroborated this finding with an arterial thrombosis rate of 10% in the 5-FU/ leucovorin-plus-bevacizumab arm vs 4.8% in the 5-FU/leucovorin-plusplacebo arm.[20] Additional interest focused on trial participants who developed thromboembolism and required anticoagulation.[ 21] Fifty-three patients from the IFL/bevacizumab arm were treated concomitantly with full-dose warfarin for a median of 218 days. The incidence of grade 3/4 hemorrhage was actually slightly lower than that seen in anticoagulated patients from the placebo group (3.8% vs 6.7%, respectively). Therefore, full-intensity anticoagulation is not a contraindication to bevacizumab use. Consistent with other bevacizumab trials, the traditional toxicities of the IFL regimen (GI and myelosuppression) were not significantly augmented with the addition of bevacizumab.
  • ECOG Study-A phase II study conducted by the Eastern Cooperative Oncology Group (ECOG's E2200) assessed the combination of IFL with bevacizumab at 10 mg/kg every 2 weeks as first-line therapy, primarily evaluating progression-free survival and response rates.[22] Patients with a history of hemorrhage or thrombosis, or on chronic anticoagulant medication were excluded. Among 87 evaluable subjects, the major toxicities included grade 3 diarrhea (17%), grade 3/4 neutropenia (35%), any hemorrhages (54%; grade 1 in > 90%), and grade 3/4 thrombosis (10%). Neither hypertension (2.3% grade 3) nor proteinuria posed clinically significant problems. The overall response rate was 49% with 6% complete remissions (as defined by Response Evaluation Criteria in Solid Tumors [RECIST]), while an additional 38% of patients had stable disease. The median progressionfree survival was 10 months. These efficacy data are concordant with the report of AVF2107 by Hurwitz et al.

FDA Approval
Based on the AVF2107 pivotal trial, the FDA approved bevacizumab for use in patients with previously untreated colorectal cancer in conjunction with 5-FU-based chemotherapy. Neither cardiovascular disease nor chronic anticoagulation are listed as contraindications in the package insert. Based on data derived from trials of bevacizumab in non-small-cell lung cancer (NSCLC), indicating a 9% risk of serious, even fatal pulmonary hemorrhage, the drug is contraindicated in patients with a recent history of hemoptysis.[23] The safety and efficacy of bevacizumab in patients with central nervous system metastases have not been evaluated. A warning concerning congestive heart failure was included in the approval, although this adverse effect was observed mostly in the context of prior or concomitant anthracycline therapy in metastatic breast cancer studies. Notably, biweekly blood pressure evaluation and urine analysis via dipstick, with 24-hour urine collection in case of 2+ proteinuria, are recommended. Per the January 2005 amended package insert, vigilance for signs and symptoms of arterial thromboembolic events including angina, myocardial infarction, transient ischemic attack, and cerebrovascular accidents is warranted due to an estimated 4.4% overall risk of such events associated with bevacizumab use. Which Chemotherapy Regimen to Use?
The FDA approval of bevacizumab is open-ended with regard to choice of chemotherapy, advising simply that bevacizumab be combined with infusional 5-FU regimens. The IFL regimen used in the pivotal AVF2107 has been largely replaced by programs utilizing infusional forms of 5-FU in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) due to their better efficacy and safety profile.[24] These regimens and their clinical outcomes are summarized in Figure 1. The excellent survival outcomes observed with 5-FU/bevacizumab in AVF2107 as well as in the aforementioned phase II experiences raise questions about the relative contribution of irinotecan to first-line 5-FU/bevacizumab and the more general need to utilize chemotherapy doublets in combination with bevacizumab. A placebo-controlled, randomized study-AVF2192g-evaluated single- agent 5-FU/leucovorin with or without bevacizumab in 209 patients deemed ineligible for combination therapy using irinotecan or oxaliplatin due to age or poor performance status.[ 25] This approach proved useful, again yielding a progression-free survival of 9.2 months in the treatment arm vs 5.5 months in the control arm, although the overall survival difference (16.6 vs 12.9 months) was not statistically significant. These survival outcomes are comparable to those reported in studies of FOLFOX or FOLFIRI regimens in untreated general populations of patients with metastatic colorectal cancer.[ 26,27] The side-effect profile of this trial again supports the observation that bevacizumab does not worsen typical 5-FU-associated side effects but is associated with an increased incidence of hypertension, doubled rate of arterial thromboembolic events (10%), and 2% incidence of GI perforation. Bevacizumab with 5-FU, therefore, enables less fit patients to enjoy survival benefits similar to persons receiving other highly active new chemotherapeutic combinations such as FOLFIRI or FOLFOX. Trials evaluating bevacizumab in combination with either FOLFOX or capecitabine (Xeloda)-oxaliplatin doublets (XELOX, CAPEOX) in patients with previously untreated metastatic colorectal cancer are either ongoing or planned. Until mature outcome data are available from these trials, the general concept of selecting a regimen based on toxicity profile, patient comorbidity, and patient preference should govern the choice of chemotherapy to combine with bevacizumab. Treatment Duration: Maintenance vs Intermittent Therapy
The intriguing concept of continuing bevacizumab therapy with sequential non-cross-resistant chemotherapy regimens is being explored. Patients in the experimental arms of the pivotal AVF2107 trial were allowed to continue bevacizumab after disease progression in combination with other chemotherapy regimens (25% of patients received oxaliplatin). Some patients have received bevacizumab for up to 3 years. No late toxic events have been observed in association with chronic bevacizumab therapy of 1 or more years. The subset of patients who continued to receive bevacizumab in conjunction with second-line oxaliplatin attained a median survival of 25 months.[28] The results of ECOG trial E3200 were announced at the American Society of Clinical Oncology (ASCO) gastrointestinal symposium in January 2005.[29] This phase III study randomized 829 patients with metastatic colorectal carcinoma progressing on first-line, irinotecan-based therapy into treatment with FOLFOX4 alone or with the addition of bevacizumab at 10 mg/kg. A third arm of single-agent bevacizumab (10 mg/kg) was discontinued after planned interim analysis due to inferior efficacy. Participants were monitored for proteinuria, and if it exceeded 500 mg/24 hours, the dose of bevacizumab was adjusted to 5 mg/kg. A survival benefit (12.5 vs 10.7 months, P = .0024) favored the experimental arm in this patient population. The toxicity analysis in the E3200 trial is consistent with results of the other bevacizumab trials in metastatic colorectal cancer (Table 2). There was no significant increase in hematologic toxicity but somewhat higher rates of nausea and vomiting (20% vs 9%) and neuropathy (15% vs 9%). The incidence of grade 3 hemorrhage was 2% in the FOLFOX4/bevacizumab arm, compared to 0% in the control arm; rates of thrombosis were identical. The incidence of bowel perforation was approximately 1% with one fatal event. Three other deaths possibly associated with bevacizumab included pneumonitis, a possible pulmonary embolism, and a brain hemorrhage complicating deep-vein thrombosis-related anticoagulation. Preliminary data regarding the ac- tivity of bevacizumab plus cetuximab (Erbitux) with or without irinotecan as second- or third-line therapy for patients with irinotecan-refractory disease- the so-called BOND-2 trial- were also presented at the January 2005 ASCO gastrointestinal malignancy symposium. A response rate of 38% with a median time to disease progression of 8.5 months was attained in the irinotecan-containing arm. An encouraging 23% response rate and 6.9-month median time to disease progression was attained in the bevacizumabcetuximab- alone arm.

Since the median time to disease progression with first-line bevacizumab therapy is consistently approaching 10 to 11 months, a practical issue of whether to continue therapy until disease progression or hold therapy after disease control has been attained (usually with 4-6 months of treatment), and retreat upon disease progression needs to be addressed. Such intermittent therapy has been demonstrated to be effective with regard to survival outcomes in the treatment of metastatic breast and non-small-cell lung cancer (NSCLC), and this strategy is already applied by oncologists treating those diseases. Comparable survival outcomes with intermittent 5-FU-based therapy vs uninterrupted therapy until disease progression also have been demonstrated in patients with metastatic colorectal cancer.[30] Whether intermittent therapy can be applied to bevacizumab-based regimens without sacrificing survival outcomes is an important yet unstudied issue.Bevacizumab and Wound Healing: Feasibility of Adjuvant Therapy
AVF2107 did not permit initiation of therapy until at least 28 days following surgery. Additional analyses of data from this pivotal phase III trial revealed that bevacizumab use was associated with wound complications in 3 of 187 patients (1.6%).[31] One patient developed dehiscence of an anastomosis despite the initiation of bevacizumab more than 2 months after surgery. However, a 10% wound complication or bleeding rate was noted in bevacizumab-treated patients who underwent major surgery (laparotomy or thoracotomy) while on study, compared with a 4% wound complication/bleeding rate in the respective subset from the placebo arm. These observations prompted a boxed warning that a safe interval for elective surgery following a dose of bevacizumab is unknown. However, the relative lack of wound complications with the reverse sequence, ie, initiation of bevacizumab following surgery, encourages evaluation of bevacizumab as adjuvant therapy. Intergroup trial E-5202 will randomize patients with molecular features of high-risk stage II colon cancer determined by microsatellite instability and abnormalities of chromosome 18q to treatment with 5-FU/leucovorin with or without bevacizumab. A large placebo-controlled, randomized study (the Multicenter International Study of Oxaliplatin/5-FU/ Leucovorin in the Adjuvant Treatment of Colon Cancer [MOSAIC]) has demonstrated improvement in 3-year disease-free survival with adjuvant chemotherapy using FOLFOX rather than 5-FU/leucovorin (78.2% vs 72.9%, P = .002) in patients with stage II/III colon carcinoma.[32] Based on the results of that trial, the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-08 protocol is evaluating adjuvant FOLFOX with or without bevacizumab. In rectal cancer, neoadjuvant chemoradiation is a reasonable standard treatment for locally advanced (ie, stage II/III) disease.[33] Therapy with antiangiogenic drugs may enhance the effects of radiotherapy, as hypoxic VEGF induction has been demonstrated in radiation-treated tumors.[34] The ability to integrate antiangiogenic agents into preoperative management is in initial phases of evaluation. Investigators from Harvard Medical School and the National Cancer Institute reported a preliminary experience in six patients with rectal adenocarcinoma.[ 35] Patients were treated with a single dose of bevacizumab (5 mg/kg) followed 2 weeks later by neoadjuvant chemoradiation with standard fractionation radiotherapy to 50.4 Gy and continuous- infusion 5-FU (225 mg/m2/d) with bevacizumab administered concurrently every 2 weeks (four doses in total). Subsequent resection was performed 7 weeks after completion of neoadjuvant treatment. No dose-limiting toxicity or perioperative complications were noted. Several physiologic parameters were measured before and after resection. The most remarkable observation was a decrease in interstitial tumor pressure measured 12 days after the initial dose of bevacizumab (from 15.0 to 4.0 2.2 mm Hg). This is believed to correlate with normalization of the function of tumor-induced blood vessels and may improve delivery of subsequent chemotherapy into the tumor interstitium as evidenced in rodent models of colon carcinoma exposed to irinotecan[ 36] and 5-FU.[37] Tumor interstitial pressure-dependent on VEGFinduced vascular permeability-has been recognized as a barrier to effective distribution of therapeutic molecules[ 38] because it obliterates the convective component of macromolecular transportation.[39] Bevacizumab re- duces vascular permeability and interstitial pressure, thus improving oxygen and large-molecule transfer into the tumor bed. This renders malignant cells more vulnerable to effects of radiation[ 40] and chemotherapy. Concluding Thoughts on Bevacizumab
In summary, the addition of bevacizumab to chemotherapy for metastatic colorectal cancer is relatively safe and significantly prolongs overall and progression-free survival (up to 10 months) with a response rate of 45% in previously untreated patients. Larger randomized studies have identified hypertension, increased risk of arterial thrombosis, bleeding, and GI perforation as important bevacizumab- specific side effects (Table 3). In approximately 1% of patients, potentially severe GI perforations may occur. These also have been reported in clinical trials of bevacizumab in other types of cancers.[41] Standard long-term anticoagulation with warfarin does not require discontinuation of bevacizumab and is not associated with excess hemorrhage. Proteinuria is not increased when compared to standard regimens. The mechanism of proteinuria is unclear; however, both anti-VEGF antibodies and soluble VEGFR-1 were shown to induce transient proteinuria in mice via a toxic mechanism on glomerular endothelium. Pathologic changes include endothelial hypertrophy, detachment from basement membrane evident on electron microscopy, and downregulation of nephrin, a protein essential for glomerular filtration.[42] Patients with clinically significant vascular disease, uncontrolled hypertension, or previous thrombosis may not be optimal candidates for treatment with this antiangiogenic agent. Other Antiangiogenic Agents in Clinical DevelopmentSU5416
SU5416 (semaxinib) is a smallmolecule inhibitor of VEGFR-2 tyrosine kinase domain designed to selectively block Flk-1/KDR receptor action.[43] In a phase I/II trial of firstline therapy for metastatic colon car- cinoma, intravenous SU5416 (at two dose levels: 85 and 145 mg/m2 twice weekly) was combined with bolus 5-FU/leucovorin (either Mayo Clinic or Roswell Park schedule) and the results were compared with subsets of the reference phase III trial of the IFL regimen published by Saltz et al for the Irinotecan Study Group.[44,45] Although a promising time to disease progression of 9 months was noted, the subsequent phase III trial of SU5416 in combination with IFL was halted at interim analysis due to lack of expected clinical benefit. Further development of SU5416 is not expected. Angiozyme
Angiozyme, a ribozyme designed to cleave VEGFR-1 mRNA, combined with IFL in a phase II trial in 83 patients with previously untreated stage IV colorectal carcinoma showed a time to disease progression of 6.2 months.[46] While the uncontrolled nature of this study makes conclusions regarding efficacy difficult, the results were not suggestive of additive benefit. Further development of this drug is uncertain. ZD6474
Despite the disheartening results of semaxinib, other VEGFR-targeting tyrosine kinase inhibitors are progressing in clinical trials. Their better efficacy may be paradoxically related to less selective affinity, encompassing even non-VEGF-associated receptors. ZD6474 is an orally bioavailable inhibitor of VEGFR-2 (IC50 = 0.04 μM), as well as VEGFR-3 (a receptor involved with lymphangiogenesis) and EGFR (IC50 = 0.5 μM), that exhibits antitumor activity in xenograft models and is currently in phase II clinical trials for lung cancer.[47] Interestingly, it produces side effects that are typical for both VEGF (hypertension, proteinuria) and EGFR (rash, diarrhea) inhibitors, although these are usually mild.[48] Asymptomatic, dose-dependent QTc-interval prolongation was observed with this compound.[49] PTK787/ZK 222584
PTK787/ZK 222584 (vatalanib), another oral tyrosine kinase inhibitor, inhibits VEGFR-1 and VEGFR-2 with IC50 < 0.08 μM (and, to a lesser extent, c-kit and platelet-derived growth factor receptor-beta) and its development is focusing on gastrointestinal tumors.[50] In phase I/II trials, it has been combined successfully with oxaliplatin- and irinotecan-based first-line chemotherapy for metastatic colorectal carcinoma. Continuous daily administration of PTK787/ZK 222584 during treatment with FOLFOX4 resulted in dose-limiting neurologic toxicity without increasing other chemotherapyspecific side effects or altering the pharmacokinetics of oxaliplatin. Median time to disease progression among 34 patients with previously untreated metastatic colorectal cancer participating in the phase II trial was 11 months, which compares favorably to bevacizumab-associated outcomes.[51] Two phase III trials of PTK787/ZK 222584 (CONFIRM-1 and -2) with FOLFOX chemotherapy in colorectal cancer have been completed and reports of survival outcomes are anticipated this year. Dose-dependent reduction in enhancement of liver metastases as assessed by dynamic contrast-enhanced magnetic resonance imaging (MRI) following treatment with PTK787/ZK 222584 may serve as a noninvasive surrogate of antiangiogenic response.[52] CEP-7055 and AE-941
CEP-7055 has been designed as a powerful (IC50 < 0.02 μM) oral inhibitor of VEGFR-1, -2, and -3 tyrosine kinase activity and is currently in phase I testing.[53] AE-941 (Neovastat) is a multitargeted compound derived from shark cartilage, which has been shown to inhibit several matrix metalloproteinases as well as interfere with VEGFR-2-dependent signaling.[54] Its clinical development is most advanced in pulmonary and renal malignancies. No dose-dependent toxicity was identified in phase I/II studies.[ 55] An interim toxicity analysis of an ongoing phase III trial in unre- sectable stage III NSCLC in combination with platinum-based chemotherapy did not reveal any excessive toxicity attributable to AE-941.[56] VEGF-Trap
A possibly more potent modality of blocking VEGF activity involves deployment of a soluble VEGF inhibitor called VEGF-Trap. The VEGFTrap molecule consists of selected immunoglobulin (Ig)-like domains of the Flt-1 and Flk-1/KDR receptors fused with the Fc portion of human IgG1, engineered to produce a compound with an extraordinarily high binding affinity in a picomolar range, while retaining favorable pharmacokinetic characteristics.[57] In a murine xenograft model of human Wilms tumor, intraperitoneal treatment with VEGF-Trap resulted in a nearly 80% decrease in mean tumor mass and induced tumor avascularity.[58] This effect was specific to malignant vasculature. Treatment with VEGF-Trap, as opposed to anti-VEGF antibody, results in a phenomenon termed "tumor stunting," in which the malignant mass is not only unable to create, but also unable to recruit, new blood vessels and becomes avascular.[59] The powerful antiangiogenic effect of VEGFTrap, with binding affinity up to 100 times that of anti-VEGF monoclonal antibodies, raises hopes of targeting larger, more advanced cancers as well as provoking clinical cytotoxic responses.[ 60] Phase I evaluation of subcutaneous VEGF-Trap at doses from 25 to 800 μg/kg twice weekly revealed a plasma half-life of 25 days and no dose-limiting toxicities.[61] Drug-related side effects included hypertension, proteinuria, and neutropenia. Stable disease was observed in a patient with renal cell carcinoma and colon carcinoma. Perspectives Several issues in clinical trial design and interpretation have been raised in conjunction with angiogenesis inhibitors. First, standard response criteria are inadequate in assessing the efficacy of these agents. Their action is cytostatic rather than cytotoxic and objective tumor responses are not usual.[62] The majority of patients will exhibit stable disease rather than a decrease in tumor volume. Therefore, time to progression (as a measure of disease stabilization) has been postulated as a more appropriate end point for studies of efficacy.[63] The traditional concept of a dose-finding phase I study may also fail in view of the lack of dose-limiting toxicities. Effective doses will usually be lower than the highest tolerated one.[64] Alternatively, physiologic parameters, such as tumor blood flow assessed by dynamic contrast-enhanced MRI, may help investigators determine the minimal effective dose.[65] In clinical trials, the antiangiogenic agents-in particular, bevacizumab- show pronounced synergism with traditional chemotherapy with acceptable additive toxicity, augmenting response rates and significantly prolonging the survival of patients with metastatic colorectal carcinoma. The combination of 5-FU with bevacizumab alone appears to result in similar survival outcomes to those associated with popular, albeit more toxic, programs incorporating irinotecan and oxaliplatin (Figure 1). This striking synergism, as already suggested by in vivo studies, may be partly due to the previously undervalued effect of bevacizumab on tumor interstitial pressure. The reduction in vascular permeability, thanks to blockade of the VEGF pathway, leads to a fall in interstitial pressure and more efficacious delivery of chemotherapy into tumor.[66] More potent inhibitors of angiogenesis such as VEGFTrap- alone or in combination with chemotherapy-may actually exert a direct tumoricidal effect. The coming years are destined to see a number of new compounds targeting the VEGFsignaling system and other molecules involved in angiogenesis. The introduction of bevacizumab into the clinic, especially if its indications expand to second-line and adjuvant settings as well as to treatment of other types of malignancies, will have a fundamental impact on practice throughout the community. Continuous surveillance of the newly identified class-specific adverse effects is necessary, and the high cost of treatment may play a major role in its availability to patients. As an aggregate, antiangiogenic modalities will hopefully energize the shift of modern oncologic therapy toward the less toxic and more effective paradigm of molecular targeting.


Dr. Kozuch receives honoraria from and owns stock in Genentech, and receives honoraria and grant support from Pfizer and Sanofi. Dr. Grossbard owns stock in Pfizer.


1. Leenders WPJ: Targetting VEGF in antiangiogenic and anti-tumour therapy: Where are we now? Int J Exp Pathol 79:339-346, 1998.
2. Connolly DT, Heuvelman DM, Nelson R, et al: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470–1478, 1989.
3. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocrine Rev 18:4-25, 1997.
4. Jakeman LB, Winer J, Bennett GL, et al: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244-253, 1992.
5. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994.
6. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990.
7. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735, 1993.
8. Kumar H, Heer K, Lee PW, et al: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4:1279-1285, 1998.
9. Werther K, Christensen IJ, Brunner N, et al: Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. Eur J Surg Oncol 26:657-662, 2000.
10. Ishigami SI, Arii S, Furutani M, et al: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78:1379- 1384, 1998.
11. Cascinu S, Staccioli MP, Gasparini G, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6:2803-2807, 2000.
12. Chin KF, Greenman J, Kumar H, et al: Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 83:1425-1431, 2000.
13. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993.
14. Warren RS, Yuan H, Matli MR, et al: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797, 1995.
15. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001.
16. Gaudreault J, Bruno R, Kabbinavar F, et al: Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing (abstract 3041). Proc Am Soc Clin Oncol 23:205, 2004.
17. Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 19:851-856, 2001.
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
20. Novotny WF, Holmgren E, Nelson B, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer (abstract 3529). Proc Am Soc Clin Oncol 23:252, 2004.
21. Hambleton J, Novotny WF, Hurwitz H, et al: Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation (abstract 3528). Proc Am Soc Clin Oncol 23:252, 2004.
22. Giantonio BJ, Levy D, O’Dwyer PJ, et al: Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as frontline therapy for advanced colorectal cancer (advCRC): Updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200 (abstract 289). Program and abstracts of the Gastrointestinal Cancers Symposium, San Francisco, January 22, 2004.
23. DeVore R, Fehrenbacher L, Herbst R, et al: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC (abstract 1896). Proc Am Soc Clin Oncol 19: 2000.
24. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
25. Kabbinavar FF, Schulz J, McCleod M, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 (abstract 3516). Proc Am Soc Clin Oncol 23:249, 2004.
26. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
27. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041- 1047, 2000.
28. Hedrick EE, Hurwitz H, Sarkar S, et al: Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC) (abstract 3517). Proc Am Soc Clin Oncol 23:249, 2004.
29. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab in combination with FOLFOX-4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract 169a). Program and abstracts of the Gastrointestinal Cancers Symposium, Hollywood, Fla, January 27, 2005.
30. Maughan TS, James RD, Kerr DJ, et al: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 361:457-464, 2003.
31. Scappaticci F, Fehrenbacher L, Cartwright T, et al: Lack of effect of bevacizumab on wound healing/bleeding complications when given 28- 60 days following primary cancer surgery (abstract 3530). Proc Am Soc Clin Oncol 23:253, 2004.
32. Andre T, Boni C, Mounedji-Boudiaf L: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004.
33. Chau I, Chan S, Cunningham D: Overview of preoperative and postoperative therapy for colorectal cancer: The European and United States perspectives. Clin Colorectal Cancer 3:19-33, 2003.
34. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999.
35. Willett CG, Boucher Y, Di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004.
36. Wildiers H, Guetens G, De Boeck G, et al: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979-1986, 2003.
37. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002.
38. Jain RK: The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 4:655-657, 1998.
39. Netti PA, Hamberg LM, Babich JW, et al: Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules. Proc Natl Acad Sci U S A 96:3137- 3142, 1999.
40. Lee CG, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000.
41. Kindler HL, Friberg G, Stadler WM, et al: Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium (abstract 86). Program and abstracts of the Gastrointestinal Cancers Symposium, San Francisco, January 22, 2004.
42. Sugimoto H, Hamano Y, Charytan D, et al: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt- 1) induces proteinuria. J Biol Chem 278:12605- 12608, 2003.
43. Annie T, Fong T, Shawver LK, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk- 1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106, 1999.
44. Miller LL, Elfring GL, Hannah AL, et al: Efficacy results of a phase I/II study of SU5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (Pts) from a phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC) (abstract 571). Proc Am Soc Clin Oncol 20:144a, 2001.
45. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000.
46. Venook A, Hurwitz H, Cunningham C, et al: Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: Results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR- 1 (angiozyme), in combination with chemotherapy (abstract 1025). Proc Am Soc Clin Oncol 22:256, 2003.
47. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655, 2002.
48. Minami H, Ebi H, Tahara M, et al: A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors (abstract 778). Proc Am Soc Clin Oncol 22:194, 2003.
49. Hurwitz H, Holden SN, Eckhardt SG, et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors (abstract 325). Proc Am Soc Clin Oncol 21:82a, 2002.
50. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000.
51. Steward WP, Thomas A, Morgan B, et al: Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer (abstract 3556). Proc Am Soc Clin Oncol 23:259, 2004.
52. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003.
53. Ruggeri B, Singh J, Gingrich D, et al: CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63:5978-5991, 2003.
54. Beliveau R, Gingras D, Kruger EA, et al: The antiangiogenic agent neovastat (AE- 941) inhibits vascular endothelial growth factor- mediated biological effects. Clin Cancer Res 8:1242-1250, 2002.
55. Latreille J, Batist G, Laberge F, et al: Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 4:231-236, 2003.
56. Lu C, Komaki R, Herbst RS, et al: A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim overall toxicity report (abstract 2665). Proc Am Soc Clin Oncol 22:663, 2003.
57. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398, 2002.
58. Huang J, Frischer JS, Serur A, et al: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 100:7785- 7790, 2003.
59. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of co-opted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 99:11399-11404, 2002.
60. Hood JD, Cheresh DA: Building a better Trap. Proc Natl Acad Sci U S A 100:8624-8625, 2003.
61. Dupont L, Schwartz J, Koutcher D, et al: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies (abstract 3009). Proc Am Soc Clin Oncol 23:197, 2004.
62. Kerbel RS: Tumor angiogenesis: Past, present, and the near future. Carcinogenesis 21:505-515, 2000.
63. Carter SK: Clinical strategy for the development of angiogenesis inhibitors. Oncologist 5(suppl 1):51-54, 2000
64. Deplanque G, Harris AL: Anti-angiogenic agents: Clinical trial design and therapies in development. Eur J Cancer 36:1713-1724, 2000.
65. Marzola P, Degrassi A, Calderan L, et al: In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10:739-750, 2004.
66. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001.